Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States and internationally. The company operates through two segments: Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. It also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, and regulatory review. In addition, the company sells beta-alanine ingredients under the CarnoSyn, TriBsynm, CarnoSyn 4X, and SR CarnoSyn names. It manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. The company's private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. Natural Alternatives International, Inc. was founded in 1980 and is headquartered in Carlsbad, California.…
Natural Alternatives: Fiscal Q1 Earnings Snapshot
Natural Alternatives International (NASDAQ: NAII) is listed on Nasdaq, where its shares trade in USD. It belongs to the Packaged Foods industry, part of the Consumer Defensive sector, and reports about 301 employees.
The shares were at 0.8760 USD on 20 November 2026, down 70.4% over 52 weeks. Its 52-week range is 0.8699 USD to 4.960 USD, and it trades at the bottom of that range.
Its market capitalisation is 5.48M USD.
Natural Alternatives International reports return on equity of -41.4%, an operating margin of -8.4% and revenue down 25.5% year over year.
Its debt exceeds its cash by 41.01M USD, a debt-to-equity ratio of 1.00. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.